Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

cancer vaccine | Image credit: IO Biotech
From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

May 3rd 2025

Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

March 31st 2025

Travis Osterman, DO, MS, FAMIA, FASCO
Leveraging AI to Optimize Precision Immunotherapy at Vanderbilt

October 25th 2024

More News

Graphic with wording "top 5 Evidence-Based Oncology articles of 2022"
December 24th 2022

Top Articles From Evidence-Based Oncology™ in 2022

In 2022, the most-read articles published in Evidence-Based Oncology™ included the latest updates in cancer treatments, the promises and challenges of technology, and a look at the shifting landscape of care delivery.
Top 5 Most-Read Immuno-Oncology Articles of 2022
December 22nd 2022

Top 5 Most-Read Immuno-Oncology Articles of 2022

AJMC Staff
In 2022, the most-read news about immuno-oncology included an FDA approval for liver cancer, research findings on other potential therapies for liver cancer, a Q&A with a COTA Healthcare executive about how real-world evidence has changed, new possibilities for patients with solid tumors, and more.
EBO logo
December 21st 2022

Data Sharing From Cancer Drug Trials Falls Short of Promises, Study Authors Say

Mary Caffrey
image of a health care provider and various icons indicating health and cost
December 13th 2022

ICYMI: Top Content From AMCP Annual Meeting

AJMC Staff
Among the conference highlights from the annual meeting of the Academy of Managed Care Pharmacy (AMCP) were an interview on chimeric antigen receptor T-cell therapies and a session on best practices for value-based contracting.
Image of a young male patient
December 8th 2022

Using Risk Factors to Guide CAR T Approach Before, After Infusion in B-ALL

Jaime Rosenberg
This paper follows the 10-year remission mark for the first child treated with CD19-targeted CAR (chimeric antigen receptor) T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL), adding promise to the notion that the technology can provide long-term durable remissions in patients who are highly refractory to chemotherapy.
ICYMI: Top Highlights From the 2022 Patient-Centered Oncology Care® Meeting
December 5th 2022

ICYMI: Top Highlights From the 2022 Patient-Centered Oncology Care® Meeting

AJMC Staff
axi-cel
December 3rd 2022

What Predicts Good Outcomes With Axi-cel? Investigators Support “Timely” Treatment

Mary Caffrey
Investigators from Fred Hutchison Cancer Research Center hoped to gain insights into what factors can predict success with axi-cel in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Abstract image of CAR T
November 23rd 2022

Drops in Serum Phosphate Levels May Help Predict Severe CRS After CAR T

Jaime Rosenberg
A new study has found that a drop in serum inorganic phosphate (iP) was an early predictor of severe cytokine release syndrome (CRS), suggesting that monitoring serum iP levels could help promote safer management of the most common toxicity associated with chimeric antigen receptor (CAR) T-cell therapy.
Stephen M. Schleicher, MD, MBA, Tennessee Oncology
November 14th 2022

Dr Stephen Schleicher: We Need to Focus More on Financial Toxicity

Maggie L. Shaw Mary Caffrey
Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, addresses the “huge problem” of financial toxicity among patients with cancer, which can be attributed in part to both the high price of targeted treatments and even from ordering only necessary testing.
graphic depicting research
November 8th 2022

Researchers Provide Management Recommendations for CRS, Other Toxicities of CAR T

Jaime Rosenberg
While chimeric antigen receptor (CAR) T-cell therapy has offered a new option and improved outcomes for patients with advanced hematologic malignancies, the treatment approach has been associated with toxicities such as cytokine release syndrome (CRS), neurotoxicity, and hematotoxicity.
CAR T
October 25th 2022

Are NK-Cell–Based Treatments the Next Approach in Immuno-Oncology?

Jaime Rosenberg
Highlighting their ability to quickly destroy malignant cells without antigen specificity, natural killer (NK) cells have been identified as an opportunity for use, particularly in cases where T cells are not effective.
Combination of Tremelimumab and Durvalumab Approved by FDA for Unresectable Liver Cancer
October 24th 2022

Combination of Tremelimumab and Durvalumab Approved by FDA for Unresectable Liver Cancer

AJMC Staff
A dual immunotherapy option of tremelimumab, sold as Imjudo, in combination with durvalumab, sold as Imfinzi, was approved by the FDA Monday for the treatment of adult patients with unresectable hepatocellular carcinoma, the most common type of liver cancer.
Image of biotechnology innovation
October 22nd 2022

Identifying ASCT-Ineligible Patients Who Could Benefit From CAR T-Cell Treatment

Jaime Rosenberg
Data suggest that the technology may be an option for patients who are ineligible for autologous stem cell transplantation (ASCT) based on certain patient characteristics, prior treatments, stem cell availability, or tumor chemosensitivity.
At Last, Artificial Intelligence Is Transforming Cancer Drug Discovery and Development
October 20th 2022

At Last, Artificial Intelligence Is Transforming Cancer Drug Discovery and Development

Dietmar Berger, MD, PhD
Review Underscores Potential and Obstacles of Universal CAR T-Cell Therapy
October 15th 2022

Review Underscores Potential and Obstacles of Universal CAR T-Cell Therapy

Rose McNulty
Despite the obstacles and risks, the review authors conclude that universal chimeric antigen receptor (CAR) T-cell therapy has the potential to play a key role and mitigate some of the limitations associated with autologous CAR T-cell therapy in cancer treatment.
CAR T
October 14th 2022

Advances and Limitations in CD20-Targeted CAR T-Cell Therapy

Rose McNulty
The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research.
Kidneys
September 30th 2022

CAR T-Cell Therapy Outcomes Are Not Impacted by Baseline Renal Function, Study Finds

Rose McNulty
Renal outcomes and chimeric antigen receptor (CAR) T-cell therapy efficacy were unaffected by baseline renal status in a cohort of patients with diffuse large B cell lymphoma, but acute kidney injury during treatment was associated with worse clinical outcomes.
Image of cancer cells
September 17th 2022

Myeloid Cells Hold Promise as Cancer Immunotherapy Targets, Review Says

Rose McNulty
The review highlights current strategies for myeloid cell targeting and novel agents targeting myeloid cells for cancer treatment.
Image of immuno-oncology
September 7th 2022

Neurofilament Light Chain Levels May Indicate Risk of CAR T–Related Neurotoxicity

Rose McNulty
A significant portion of patients who receive chimeric antigen receptor (CAR) T-cell therapy experience immune effector cell–associated neurotoxicity syndrome, and this recent study suggests neurofilament light chain protein levels may hold promise as a biomarker to identify at-risk patients.
targeted cancer therapy
September 2nd 2022

Which Chemo-IO Combo Is Optimal in First-line Esophageal Cancer?

Jaime Rosenberg
The review of 5 phase 3 randomized controlled trials found that overall, the combination treatments improved survival outcomes while eliciting more, but manageable, side effects.
syringe in a bag
August 30th 2022

Replacing White Bagging Mandates With Market Competition Will Improve Patient Outcome

Wayne Winegarden, PhD
Wayne Winegarden, PhD, of the Pacific Research Institute, explains the harm that white bagging policies cause health systems and how replacing them with new measures to boost market competition could help patients.
Image of immunotherapy
August 21st 2022

CAR T-Cell Therapy Outcomes Likely Not Influenced by Race/Ethnicity, Obesity

Jaime Rosenberg
Researchers studied data from 5 phase 1 studies that took place between 2012 and 2021, comprising 139 infusions among patients with B-cell acute lymphoblastic leukemia who received chimeric antigen receptor (CAR) T-cell treatment.
Image of a woman with breast cancer
August 14th 2022

Targeted Treatment for Breast Cancer Explored in New Study

Jaime Rosenberg
Despite advances made against the disease, researchers note that breast cancer still remains a top cause of cancer-related mortality in women around the world.
Image of a target
August 9th 2022

CAR T Outcomes Not Significantly Affected by rrDLBCL Subgroup

Jaime Rosenberg
With 40% of patients with diffuse large B-cell lymphoma experiencing relapsed or refractory disease (rrDLBCL), researchers highlighted the promise of chimeric antigen receptor (CAR) T-cell therapy for these patients.
lymphoma
August 4th 2022

Three CAR T-Cell Trials, 2 Outcomes, for Second-line LBCL Therapy

Jaime Rosenberg
Both the ZUMA-7 trial for axicabtagene ciloleucel—approved for second-line treatment earlier this year—and the TRANSFORM trial for lisocabtagene maraleucel showed significant improvement over standard of care for large B cell lymphoma (LBCL), while the BELINDA trial for tisagenlecleucel did not.
Amila Patel, PharmD
July 29th 2022

Dr Amila Patel Highlights Findings on Disparities in Immunotherapy Delivery

Laura Joszt, MA
Data presented at the American Society of Clinical Oncology annual meeting found non-White patients are less likely to receive immunotherapy for head and neck cancer, said Amila Patel, PharmD, chief clinical officer, Navigating Cancer.
CAR T image
July 25th 2022

Fungal Infections Rarer, Linked With Worse Prognosis in Patients Receiving CAR T-Cell Therapy

Jaime Rosenberg
Overall, infections occurred in 18.42% of cases and typically occurred within the first month, significantly dropping from then on.
Melissa L. Johnson, MD
July 22nd 2022

Dosing Study of Modakafusp Alfa Shows Promise in Solid Tumors; Tests Planned With Checkpoint Inhibitors

Mary Caffrey
Manish Patel, MD
July 22nd 2022

Lucitanib With Nivolumab Sees Responses in Gynecological Cancer Treatment

Mary Caffrey
Frederick L. Locke, MD
July 22nd 2022

Data Indicate Lower Response Rates to Axi-cel Among Black Patients

Mary Caffrey
<123456789
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo